{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:03:34Z","timestamp":1790129014692,"version":"4.0.1"},"reference-count":9,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.neurot.2026.e01072","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:51:46Z","timestamp":1789087906000},"page":"e01072","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Author response to Commentary on \"Long-term safety and efficacy of deoxycytidine\/deoxythymidine in treatment of POLG-related disorders\""],"prefix":"10.1016","volume":"23","author":[{"given":"Kenneth A.","family":"Myers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Buhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula J.","family":"Waters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurot.2026.e01072_bib1","doi-asserted-by":"crossref","first-page":"e01048","DOI":"10.1016\/j.neurot.2026.e01048","article-title":"Use of nucleoside therapy for mitochondrial DNA depletion\/deletion syndrome (MDDS)","volume":"23","author":"Hirano","year":"2026","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurot.2026.e01072_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2026.e00945","article-title":"Long-term safety and efficacy of deoxycytidine\/deoxythymidine in treatment of POLG-related disorders","volume":"23","author":"Cheung","year":"2026","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurot.2026.e01072_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s11689-020-09349-8","article-title":"Development of an adapted Clinical Global Impression scale for use in Angelman syndrome","volume":"13","author":"Kolevzon","year":"2021","journal-title":"J Neurodev Disord"},{"key":"10.1016\/j.neurot.2026.e01072_bib4","article-title":"Delta power analysis in EEG of patients with mitochondrial DNA depletion disorders","volume":"66","author":"Minato","year":"2025","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurot.2026.e01072_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1260496","article-title":"Nucleoside supplements as treatments for mitochondrial DNA depletion syndrome","volume":"12","author":"Dombi","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.neurot.2026.e01072_bib6","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202300650RR","article-title":"Deoxyribonucleoside treatment rescues EtBr-induced mtDNA depletion in iPSC-derived neural stem cells with POLG mutations","volume":"37","author":"Kristiansen","year":"2023","journal-title":"FASEB J"},{"key":"10.1016\/j.neurot.2026.e01072_bib7","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/acn3.39","article-title":"GRIN2A mutation and early-onset epileptic encephalopathy: personalized therapy with memantine","volume":"1","author":"Pierson","year":"2014","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurot.2026.e01072_bib8","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/brain\/awac380","article-title":"Randomized placebo-controlled crossover trial of memantine in children with epileptic encephalopathy","volume":"146","author":"Schiller","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2026.e01072_bib9","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.15252\/emmm.201404092","article-title":"Deoxypyrimidine monophosphate bypass therapy for thymidine kinase 2 deficiency","volume":"6","author":"Garone","year":"2014","journal-title":"EMBO Mol Med"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926002424?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926002424?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:07:56Z","timestamp":1790125676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747926002424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":9,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1878747926002424"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e01072","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Author response to Commentary on \"Long-term safety and efficacy of deoxycytidine\/deoxythymidine in treatment of POLG-related disorders\"","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e01072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00945","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e01048","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e01072"}}